Imaging the transition between pre-planetary and planetary nebulae: : Integral Field Spectroscopy of hot post-AGB stars with NIFS

This is a pre-copyedited, author-produced PDF of an article accepted for publication in Monthly Notices of the Royal Astronomical Society following peer review. The version of record [T. M. Gledhill, and K. P. Forde, 'Imaging the transition between pre-planetary and planetary nebulae: integral field spectroscopy of hot post-AGB stars with NIFS', MNRAS, Vol. 447 (2): 1080-1095, February 2015] is available online at: https://doi.org/10.1093/mnras/stu2493.We present 2 to 2.4 micron integral field spectroscopy of a sample of hot post-AGB stars with early-B spectral types, using the NIFS instrument on Gemini North. These stars are just beginning to ionize their immediate environments and turn into planetary nebulae (PNe).We use molecular hydrogen emission lines together with hydrogen and helium recombination lines to explore the distribution of molecular and atomic gas and the extent of the developing ionized region. We see a range of evolutionary stages: IRAS 18062+2410 and IRAS 18379-1707 have recently developed compact and unresolved regions of photoionized H within axisymmetric molecular envelopes, with the former object increasing its Br-Gamma flux by a factor of 5.3 in 14 years; IRAS 22023+5249 and IRAS 20462+3416 have extended Br-Gamma nebulae and in the latter object only weak H2 emission remains; IRAS 19336-0400 is at a more advanced stage of PN formation where H2 is mostly dissociated and we see structure in both the H and He recombination line nebulae. IRAS 19200+3457 is the only object not to show the He I line at 2.058 micron and is probably the least evolved object in our sample; the H2 emission forms a ring around the star and we suggest that this object may be a rare example of a "round" pre-PN in transition to a "round" PN.Peer reviewedFinal Accepted Versio

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer.

ObjectivesTo examine the cost-effectiveness of primary debulking surgery (PDS) when compared to neoadjuvant chemotherapy (NACT) in the management of epithelial ovarian cancer (EOC) using Surveillance, Epidemiology, and End Results data linked to Medicare claims (SEER-Medicare).MethodsUsing a Markov model, the cost-effectiveness of PDS was compared to that of NACT. We modeled cost and survival inputs using data from women in the SEER-Medicare database with ovarian cancer treated by either PDS or NACT between 1992 and 2009. Direct and indirect costs were discounted by an annual rate of 3%. Utility weights were obtained from published data. The incremental cost-effectiveness ratio (ICER) of PDS compared to NACT was calculated.ResultsIn our model, women with stage IIIC EOC had a higher mean adjusted treatment cost for PDS when compared to NACT ($31,945 vs$30,016) but yielded greater quality-adjusted life-years (QALYs) (1.79 vs 1.69). The ICER was $19,359/QALY gained. Women with stage IV EOC had a higher mean adjusted treatment cost following PDS when compared to NACT ($31,869 vs $27,338) but yielded greater QALYs (1.69 vs 1.66). The ICER was$130,083/QALY gained. A sensitivity analysis showed that for both PDS and NACT the ICER was sensitive to incremental changes in the utility weight.ConclusionPDS is significantly more cost-effective for women with stage IIIC when compared to NACT. In women with stage IV EOC, PDS is also more cost-effective though the QALYs gained are much more costly and exceed a $50,000 willingness to pay

The White House Counsel and Whitewater: Government Lawyers and the Scope of Privileged Communications

From the beginning of the Clinton Administration, the matters known collectively as Whitewater have almost constantly bedeviled the President and his staff, as well as the private attorneys who represent the President. Within the past two years, the investigations into Whitewater matters have given rise to two prominent controversies involving attempts to review the substance of between the lawyers who represent the President in his official capacity-the members of the Office of the White House Counsel-and those who represent him in his private capacity. One dispute involved a subpoena from a Senate committee, and the other involved a federal grand jury subpoena. The White House resisted both of these subpoenas, invoking the attorney-client privilege and the work-product doctrine. Each of these controversies raised a number of novel legal questions about the President\u27s relationship with the lawyers in the Office of the White House Counsel as well as the relationship between those lawyers and the President\u27s private counsel. Obviously, when the President seeks legal advice from his private lawyers, he (like any other citizen) can assert the attorney-client privilege in order to prevent the disclosure of those communications in a later court proceeding. But does the privilege also apply to communications between the President and lawyers who work for the President on the White House staff and are paid by the taxpayers? Does it matter if the party seeking the notes of such a communication is a congressional committee or a federal grand jury? Is any privilege waived if a non-lawyer member of the White House staff is present at the time of the communication? May the President\u27s communications with White House lawyers be discovered if these lawyers later share them with his private lawyers? Does the work-product doctrine or the executive privilege also apply to any such communications? In addition to the legal questions that were raised, the controversies themselves-as well as the way in which one of them was resolved-raised certain issues about the practical realities of raising a privilege claim. Do political realities make it impossible for the White House to raise a claim of privilege, no matter how valid that claim may be

A Sharing- and Competition-Aware Framework for Cellular Network Evolution Planning

Mobile network operators are facing the difficult task of significantly increasing capacity to meet projected demand while keeping CAPEX and OPEX down. We argue that infrastructure sharing is a key consideration in operators' planning of the evolution of their networks, and that such planning can be viewed as a stage in the cognitive cycle. In this paper, we present a framework to model this planning process while taking into account both the ability to share resources and the constraints imposed by competition regulation (the latter quantified using the Herfindahl index). Using real-world demand and deployment data, we find that the ability to share infrastructure essentially moves capacity from rural, sparsely populated areas (where some of the current infrastructure can be decommissioned) to urban ones (where most of the next-generation base stations would be deployed), with significant increases in resource efficiency. Tight competition regulation somewhat limits the ability to share but does not entirely jeopardize those gains, while having the secondary effect of encouraging the wider deployment of next-generation technologies

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer

OBJECTIVES: To examine the cost-effectiveness of primary debulking surgery (PDS) when compared to neoadjuvant chemotherapy (NACT) in the management of epithelial ovarian cancer (EOC) using Surveillance, Epidemiology, and End Results data linked to Medicare claims (SEER-Medicare). METHODS: Using a Markov model, the cost-effectiveness of PDS was compared to that of NACT. We modeled cost and survival inputs using data from women in the SEER-Medicare database with ovarian cancer treated by either PDS or NACT between 1992 and 2009. Direct and indirect costs were discounted by an annual rate of 3%. Utility weights were obtained from published data. The incremental cost-effectiveness ratio (ICER) of PDS compared to NACT was calculated. RESULTS: In our model, women with stage IIIC EOC had a higher mean adjusted treatment cost for PDS when compared to NACT ($31,945 vs$30,016) but yielded greater quality-adjusted life-years (QALYs) (1.79 vs 1.69). The ICER was $19,359/QALY gained. Women with stage IV EOC had a higher mean adjusted treatment cost following PDS when compared to NACT ($31,869 vs $27,338) but yielded greater QALYs (1.69 vs 1.66). The ICER was$130,083/QALY gained. A sensitivity analysis showed that for both PDS and NACT the ICER was sensitive to incremental changes in the utility weight. CONCLUSION: PDS is significantly more cost-effective for women with stage IIIC when compared to NACT. In women with stage IV EOC, PDS is also more cost-effective though the QALYs gained are much more costly and exceed a $50,000 willingness to pay

Rainbows: A primary health care initiative for primary schools

Within the current Australian health system is the understanding of a need to change from the predominate biomedical model to incorporate a comprehensive primary health care centred approach, embracing the social contexts of health and wellbeing. Recent research investigated the benefits of the primary health care philosophy and strategies in relation to the Rainbows programme which addresses grief and loss in primary school aged students in Western Australia. A multidisciplinary collaboration between the Western Australian Departments of Health and Education enabled community school health nurse coordinators to train teacher facilitators in the implementation of Rainbows, enabling support for students and their parents. The results of this qualitative study indicate that all participants regard Rainbows as effective, with many perceived benefits to students and their families

Amino acids in the uterine luminal fluid reflects the temporal changes in transporter expression in the endometrium and conceptus during early pregnancy in cattle

In cattle, conceptus-maternal interactions are critical for the establishment and maintenance of pregnancy. A major component of this early interaction involves the transport of nutrients and secretion of key molecules by uterine epithelial cells to help support conceptus development during the peri-implantation period of pregnancy. Objectives were to: 1) analyze temporal changes in the amino acid (AA) content of uterine luminal fluid (ULF) during the bovine estrous cycle; 2) understand conceptus-induced alterations in AA content; 3) determine expression of AA transporters in the endometrium and conceptus; and 4) determine how these transporters are modulated by (Progesterone) P4. Concentrations of aspartic acid, arginine, glutamine, histidine, lysine, isoleucine, leucine, phenylalanine and tyrosine decreased on Day 16 of the estrous cycle but increased on Day 19 in pregnant heifers (P < 0.05). Glutamic acid only increased in pregnant heifers on Day 19 (P,0.001). Asparagine concentrations were greater in ULF of cyclic compared to pregnant heifers on Day 7 (P < 0.05) while valine concentrations were higher in pregnant heifers on Day 16 (P < 0.05). Temporal changes in expression of the cationic AA transporters SLC7A1 SLC7A4 and SLC7A6 occurred in the endometrium during the estrous cycle/early pregnancy coordinate with changes in conceptus expression of SLC7A4, SLC7A2 and SLC7A1 (P < 0.05). Only one acidic AA transporter (SLC1A5) increased in the endometrium while conceptus expression of SLC1A4 increased (P < 0.05). The neutral AA transporters SLC38A2 and SLC7A5 increased in the endometrium in a temporal manner while conceptus expression of SLC38A7, SLC43A2, SLC38A11 and SLC7A8 also increased (P < 0.05). P4 modified the expression of SLC1A1, -1A4, -1A5, -38A2 , -38A4, -38A7, -43A2, -6A14, -7A1, -7A5 and -7A7 in the endometrium. Results demonstrate that temporal changes in AA in the ULF reflect changes in transporter expression in the endometrium and conceptus during early pregnancy in cattle, some of which are modified by P4. © 2014 Forde et al

Molecular mimicry of brucella melitensis epitopes in mouse and human arthritis

Brucellosis is one of the most frequent zoonosis worldwide. Infection is transferable to humans, where brucellosis is associated with high incidence of osteoarticular disease including osteomyelitis, arthritis and spondyloarthritis. Peripheral arthritis and sacroiliitis often develop in patients with no or low count of live Brucella. Recently, we demonstrated that mice develop spontaneous arthritis several weeks after acute infection when bacteria are already eradicated. We aim to decipher immune mechanism of the brucellosis-associated delayed arthritis that has not been elucidated so far

Molecular mimicry of brucella melitensis epitopes in mouse and human arthritis

Brucellosis is one of the most frequent zoonosis worldwide. Infection is transferable to humans, where brucellosis is associated with high incidence of osteoarticular disease including osteomyelitis, arthritis and spondyloarthritis. Peripheral arthritis and sacroiliitis often develop in patients with no or low count of live Brucella. Recently, we demonstrated that mice develop spontaneous arthritis several weeks after acute infection when bacteria are already eradicated. We aim to decipher immune mechanism of the brucellosis-associated delayed arthritis that has not been elucidated so far